Moreover, the capacity of HMBA-treated NK cells to kill tumor targets that largely depend on NKG2D/NKG2DL interactions, such as T-ALL or K562 cells, was drastically reduced. This evidence concerns the gene KLRK1 and acute lymphoblastic leukemia.